The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBPET.L Regulatory News (BPET)

  • There is currently no data for BPET

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Results

30 Mar 2011 07:00

RNS Number : 8563D
F&C Private Equity Trust PLC
30 March 2011
 



To: Stock Exchange

For immediate release:

30 March 2011

 

F&C Private Equity Trust plc

Preliminary Announcement for the Year to 31 December 2010 

 

F&C Private Equity Trust plc today announces its unaudited financial results for the year ended 31 December 2010.

 

Financial Highlights 

·; NAV total return for the year of 10.5 per cent for the Ordinary Shares

 

·; NAV total return for the year of 10.0 per cent for the Restricted Voting Shares

 

Chairman's Statement

 

2010 was a year of steady recovery in the fortunes of your Company. The net assets of the Company as at 31 December were £169.7 million. The Ordinary Share Pool had net assets of £164.8 million giving a fully diluted net asset value ('NAV') per share of 225.43p and an NAV total return for the year of 10.5 per cent. The net assets of the Restricted Voting Pool were £4.9 million giving an NAV per share of 7.29p which, together with the special dividend of 1.0p per share paid on 7 May 2010, gives an NAV total return for the year of 10.0 per cent. As previously intimated, another special dividend of 1.3p per Restricted Voting Share was paid on 11 January 2011. A final dividend of 0.95p per Ordinary Share is recommended for payment on 10 June 2011 to those shareholders on the register on 20 May 2011.

 

The measures which the Company undertook during 2009, including a limited sale of some positions in funds as well as the £30 million issue of Zero Dividend Preference Shares, have allowed it to build value for shareholders during 2010. Specifically, we have continued to meet all obligations as commitments are drawn down by private equity funds without putting any strain on the Company's financial resources. Additionally, as envisaged, we have also been able to make selective new investments whilst reducing the total of outstanding commitments in both absolute and relative terms. At the end of 2010 the Company had outstanding undrawn commitments of £89.3 million. Given the rate of investment, we expect a significant proportion of this to remain uncalled. It is also likely that the period over which this sum can be called will be extended as funds which are underinvested approach investors with proposals to extend investment periods. Both factors improve the manageability of what is a quickly diminishing 'burden' of commitments.

 

The Company had total investment assets of £210.9 million as at 31 December 2010. Many of these investments are maturing and we expect significant realisations during 2011. To the extent that drawdowns are not fully funded by realisations from the portfolio we have the ability to use the Company's revolving credit facility. At 31 December 2010 £29 million of the £40 million facility was available. The Ordinary Share Pool had net debt of £9.5 million at the year end. Including the accrued liability of the Zero Dividend Preference Shares of £31.8 million the Company's gearing stood at 20.0 per cent. As recovery in the value of the portfolio continues, shareholders should benefit from this moderate level of gearing.

 

The Company's positioning in the mid market of international private equity, with most of its investments in Europe, has been of considerable benefit. Specifically, throughout the recession there has been ongoing activity in the mid market, albeit at much lower levels than before the financial crisis, and this has allowed the managers that we are backing to initiate new investments and to realise mature ones. The maximum size of management buy-outs, the main medium for private equity investment, has been effectively capped by the banks' limitations on their exposure to individual private companies and also to the private equity asset class as a whole, although this situation appears to be improving as indicated by the steady recovery in the volume of deals. There is now a greater appreciation of the benefits of the mid market from those who had previously preferred larger deals.

 

Because of the breadth of the Company's portfolio, it has been exposed to a number of companies operating in niche markets where strong growth has persisted through the recession. Although the portfolio has significant exposure to Euro zone countries, the intermittent turbulence in national economies struggling with deficits has not offset the growth characteristics of the overall portfolio.

 

The Board considers that the Company's progress over the last year has been creditable and that both the short and longer term asset value growth ranks the Company highly amongst comparable listed private equity fund of funds. It is therefore a source of puzzlement that the discount is barely changed on the situation one year ago when we were emerging from a severe financial crisis. We are confident that the Company's strong fundamentals will in due course be accorded a more appropriate share price rating. The private equity team at F&C has managed the Company for 12 years and has been, and remains, integral to sustaining its strong track record.

 

Mark Tennant

Chairman

Manager's Review

 

2010 saw substantial progress in the Company's portfolio against a background of considerable challenges for many businesses and investors. The overall portfolio is almost entirely invested in the European mid market with a small number of additional investments in venture capital and global and US focused funds. The portfolio has therefore been a good exemplar of the benefits of the European mid market, namely that it is extremely broad with thousands of companies which could benefit from private equity and that, relative to the size of the opportunity, the number and size of specialist funds is small creating a favourable dynamic for investment. This innate inefficiency has led the mid market to offer companies more cheaply. In addition there has been a preference to use more moderate levels of debt than is usual for larger buy-outs. There are also large numbers of emerging managers spread across Europe which provide new highly focused means of participating in this opportunity. Since its inception, F&C Private Equity Trust has focused on the mid market tier and this underpins its relatively strong performance.

 

The current portfolio is well balanced, covering a range of funds that encompass most of the European private equity geographies and styles. The underlying companies cover many different sectors and business models. The unifying theme is that these companies are capable of supernormal growth in profits and that they have management and owners whose interests are as closely aligned as it is possible to be. As the portfolio matures it will be necessary to redeploy realised funds into fresh investments so that there is a foundation for net asset value growth and cash inflow for the period perhaps three to five years in the future. We must perform a balancing act managing the level of outstanding commitments such that they give the Company ongoing involvement in fresh deals but also do not impose too much of a liability. Since the Company's inception 12 years ago we have managed this balance successfully by having some periods where there were many new investments and others where we have been highly selective. Presently we are in a period where we are concentrating primarily on proven strong managers from within our existing cohort, although there will always be room for outstanding new managers. We are also looking to build up the component of the portfolio invested in co-investments, which has been a source of strong returns. Currently only 13 per cent of the portfolio is invested directly in private companies, well below the Company's stated limit of 33 per cent. Dealflow in co-investments has been good in recent months.

 

New Investments

Only three new investments were made during 2010. In June we invested £2.1 million into the convertible loan stock of Norway based helicopter operator Blueway. We invested alongside the leading Norwegian private equity group, Reiten. Our investment has a coupon of 12.0 per cent and carries the right to convert into 2.9 per cent of the equity. The company is ahead of budget and has won major new contracts for Norwegian electricity grid infrastructure projects and has successfully implemented its major Shell Nigeria contract. In July we committed €4.6 million to the Aurora Fund, a secondaries fund focusing on the European mid market, managed by the same team as F&C Private Equity Trust. The original portfolio of the Aurora Fund was acquired at a 63 per cent discount to asset value. Since then the underlying companies have performed well and we have been able to value the portfolio in line with IPEV guidelines, giving an uplift to 2.3x cost.

 

During the year we made a fresh commitment of £7.0 million to the Inflexion 2010 Buy-out Fund. Inflexion has been one of our more significant managers since we backed its first fund in 2003. This is the fourth Inflexion fund in which we have invested. We have also co-invested with them on four occasions, including two strong realisations; Viking Moorings and ICS.

 

Drawdowns

Total drawdowns over the course of 2010 were £43.6 million. This compares with £20.6 million in 2009. The new investments are, as usual, extremely diverse. A number of the larger investments illustrate the portfolio's breadth.

 

In the UK, drawdowns totalled £15.1 million. Reflecting the balance of the economy, a number of the larger investments were into service companies. Examples include VPS (£0.6 million TDR Capital II), protection services for vacant properties, 2e2 (£1.2 million Hutton Collins II & III), IT services, Chemigraphic (£1.1 million RJD II), services to electronics manufacturers, and City Sprint (£0.7 million Dunedin II), same day courier and logistics. There were also a number of investments with a retail or consumer aspect; Paperchase (£0.8 million Primary Capital III), stationery and greeting card retailer with 65 stores, Café Nero (£0.9 million Hutton Collins Capital III), a chain of 400 coffee shops, Verdant Leisure (£0.6 million RJD II), caravan parks, and Stonegate (£0.9 million TDR Capital II), a chain of 333 managed pubs. Healthcare, which has been a strong sector for new deals in recent years, was represented by Active Assistance (£1.1 million August Equity II), a company providing live in care for people with spinal cord injuries.

 

The European part of the portfolio called £22.9 million. These again were a mixture of consumer oriented investments but also included some services and manufacturers. The largest investment was Vizada (£1.5 million Hutton Collins II & III), the French based satellite services company formed from the merger of subsidiaries of France Telecom and Telenor. In the consumer area investments were made in Odlo (£1 million Herkules, Norway), thermal sports underwear, and in Kaffee Partner (£0.7 million Capvis III, Germany), coffee and water dispensers. In the manufacturing sector a significant investment was made in Wittur (£0.7 million Capvis III, Germany), components for the lift industry.

 

The US and global funds part of the portfolio was fairly active with drawdowns totalling £5.6 million. Notable among the larger investments were Indian generics pharmaceutical company Famy (£0.3 million) and Buchang Pharmaceutical (£0.3 million), the largest producer of traditional Chinese medicine in China. Both were made by AIF Asia Capital III.

 

Realisations

Total realisations in 2010 were £22.6 million. This is slightly below the £27.8 million achieved in both 2009 and 2008. The average total realisations for the recessionary years has therefore been £26.1 million. We expect that the flow of realisations will improve from here as confidence picks up and the recovery becomes firmly established in all markets.

 

There were two realisations from our co-investment portfolio. In March, Growth Capital Partners sold environmental consultancy Entec to Amec. This returned £3.0 million, achieving an investment multiple of 2.0x and an IRR of 30 per cent. In June, Inflexion sold nursing and doctors agency ICS to Blackstone. This returned £6.4 million, achieving an overall investment multiple of 2.5x and an IRR of 70 per cent. Both of these investments were relatively short holds, spanning the recessionary period and providing proof that value creation is possible even with a challenging macro-economic background.

 

There were several other individual realisations from a broad range of funds. The larger exits included Teaching Personnel, sold by RJD II to Graphite, returning £1.4 million. This teacher agency achieved an investment multiple of 3.1x and an IRR of 49 per cent. In the pharmaceutical sector, Life Science Partners III sold GI specialist Movetis to Shire Pharmaceuticals. The return was £1.4 million giving an investment multiple of 4.0x and an IRR of 50 per cent. August Equity I sold publishing company Imagine back to its management. The final stage of this yielded £0.7 million giving a total investment multiple of 2.0x and an IRR of 31 per cent.

 

Valuation Changes

The uplift in valuation over the year was £23.5 million, raising the total value of the portfolio to £210.9 million at the year end. The influence of foreign exchange movements was minor, with an adverse impact of £1.3 million or 0.75 per cent over the year.

 

The major movements in valuation came from a variety of sources. The sale of ICS boosted the valuation by £2.4 million, the Aurora Fund's strong start added £2.2 million and the revaluation of co-investment Lifeways, our supported living investment, contributed £1.5 million. Substantial fund uplifts included Chequers Capital XV (£1.6 million), Warburg Pincus IX (£1.3 million), Blue Point Capital Partners II (£1.1 million), and Argan Capital (£1.0 million). Of particular note was our venture capital fund investment in SEP III, which increased in value by £1.3 million. This reflects the recently announced sale of Biovex, the anti-cancer company, to Amgen.

 

It was not, however, all one way traffic and there have been some downgrades. Our remnant holding in Viking Moorings has been written down to zero, a downgrade over the year of £2.6 million, to reflect challenging trading conditions. Encouragingly, recent news from the company is better and we would expect to recover some of this investment in due course. Our position in Penta Co-investment fund has been reduced by £1.0 million for a variety of recession related difficulties in the portfolio. Whittan, the metal locker and pallet racking system company, has felt some late cycle impact and has been reduced by £1.0 million. Nmas1, one of our Spanish investments is down by £0.5 million and Pinebridge Global Emerging Markets Fund III is down by £0.4 million. These adjustments reflect both the travails of the Spanish economy and the considerable difficulty of implementing private equity successfully in emerging markets.

 

Financing

The Company's long term policy of financing the drawdown of commitments from the proceeds of realised investments and, when necessary, the use of borrowing has worked well through a challenging period. Exits have held up well and we expect that 2011 will yield significantly more than the average of the previous three years. The outstanding commitments total appears superficially large at £89.3 million but it is unlikely that all of this amount will be drawn as the rate of deployment of funds has been slower than expected and not all funds will be able to extend their investment periods if they have not invested all commitments. Considering commitments, in absolute terms the total is lower than at any time for five years and relative to the net assets of the Company lower than at any time in the Company's history. The Company's £40 million revolving credit facility is due for renewal in April next year. The banking environment has shown some recent signs of improvement and we are hopeful that we will be able to arrange a new facility of similar size and on similar terms. The Company has a portfolio of unusual breadth and good quality in the mid market of Europe and consequently we periodically attract unsolicited approaches to buy selected positions. There is no need to contemplate any sales to the secondary market but it is a perfectly viable source of capital or means of effecting a portfolio reorganisation should conditions require it.

 

Outlook

The international private equity market has experienced a significant shift in focus towards the mid market. Much of the current activity is centred on this segment and, given the preference of the major banks to reduce their exposures to the asset class and to limit their hold level for an individual credit, we would expect the mid market to continue to be relatively more important. This new found fashionability could lead to extra competition for new deals but it could also provide numerous exits for many of the mature holdings held within our funds and as direct positions. Confidence within the wider business community is on a rising trend but conditions vary from sector to sector. Generalising this, current trends appear to favour export oriented companies and provide substantial challenges to many companies with a consumer exposure.

 

Interest rates remain at exceptionally low levels but, with rising inflation and economic recovery becoming more established quarter by quarter, this cannot be expected to persist for the long term although significant increases seem unlikely in the short term. Management buy-outs factor in higher interest rates for the future and the main constraint is the availability rather than the price of credit. Dealflow for the funds in the portfolio and for co-investments is steadily improving. The combination of this and the expertise of our investment partners provide a good foundation for a significant and enduring recovery in asset value in 2011.

 

 

Hamish Mair

Investment Manager

F&C Investment Business Limted

 

 

 

For more information, please contact:

 

 

Hamish Mair

0131 718 1184

Gordon Hay Smith

0131 718 1018

hamish.mair@fandc.com / gordon.haysmith@fandc.com

 

F&C Private Equity Trust plc

 

Consolidated Statement of Comprehensive Income for the

year ended 31 December 2010

 

 

Unaudited

 

Revenue

£'000

Capital

£'000

Total

£'000

 

Capital gains on investments

Gains on investments held at fair value

-

18,938

18,938

Currency gains

-

1,000

1,000

-

19,938

19,938

Revenue

Investment income

2,170

-

2,170

Other income

41

-

41

Total income

2,211

19,938

22,149

Expenditure

Investment management fee

(420)

(1,262)

(1,682)

Other expenses

(693)

-

(693)

Total expenditure

(1,113)

(1,262)

(2,375)

Profit before finance costs and taxation

1,098

18,676

19,774

Finance costs

(160)

(3,263)

(3,423)

Profit before taxation

938

15,413

16,351

Taxation

(239)

268

29

Profit for year/total comprehensive income

699

15,681

16,380

Return per Ordinary Share - Basic & Diluted

0.96p

21.02p

21.98p

Return per Restricted Voting Share - Basic

0.00p

0.73p

0.73p

 

 

F&C Private Equity Trust plc

 

Consolidated Statement of Comprehensive Income for the

year ended 31 December 2009

 

 

Audited

 

Revenue

£'000

Capital

£'000

Total

£'000

 

Capital losses on investments

Losses on investments held at fair value

-

(12,896)

(12,896)

Currency gains

-

3,767

3,767

-

(9,129)

(9,129)

Revenue

Investment income

1,813

-

1,813

Other income

42

-

42

Total income

1,855

(9,129)

(7,274)

Expenditure

Investment management fee

(356)

(1,067)

(1,423)

Other expenses

(720)

-

(720)

Total expenditure

(1,076)

(1,067)

(2,143)

Profit/(loss) before finance costs and taxation

779

(10,196)

(9,417)

Finance costs

(195)

(709)

(904)

Profit/(loss) before taxation

584

(10,905)

(10,321)

Taxation

(164)

164

-

Profit for year/total comprehensive income

420

(10,741)

(10,321)

Return/(loss) per Ordinary Share - Basic & Diluted

0.58p

(14.89)p

(14.31)p

Return per Restricted Voting Share - Basic

0.00p

0.03p

0.03p

 

F&C Private Equity Trust plc

 

Balance Sheets

 

 

 

As at 31 December 2010(Unaudited)As at 31 December 2009

(Audited)

 

Group

Company

Group

Company

£'000

£'000

£'000

£'000

Non-current assets

Investments at fair value through profit or loss

210,914

210,864

171,011

170,961

Subsidiary undertaking

-

53

-

50

210,914

210,917

171,011

171,011

Current assets

Other receivables

19

18

157

195

Cash and cash equivalents

2,681

2,679

13,509

13,471

2,700

2,697

13,666

13,666

Current liabilities

Other payables

(12,130)

(12,130)

(1,106)

(1,106)

Amounts due to subsidiary

-

(31,774)

-

(28,992)

Net current (liabilities)/assets

(9,430)

(41,207)

12,560

(16,432)

Total assets less current liabilities

201,484

169,710

183,571

154,579

Non-current liabilities

Zero dividend preference shares

(31,774)

-

(28,992)

-

Net assets

169,710

169,710

154,579

154,579

Equity

Called-up ordinary share capital

1,394

1,394

1,394

1,394

Special distributable capital reserve

15,679

15,679

15,679

15,679

Special distributable revenue reserve

36,686

36,686

37,357

37,357

Capital redemption reserve

664

664

664

664

Capital reserve

114,495

114,497

98,814

98,813

Revenue reserve

792

790

671

672

Shareholders' funds

169,710

169,710

154,579

154,579

Net asset value per Ordinary Share - Basic & Diluted

228.02p

206.84p

Net asset value per Restricted Voting Share - Basic

 

7.29p

 

7.56p

 

F&C Private Equity Trust plc

Statements of Changes in Equity

For the year ended 31 December 2010

 

Group

 

 

 

Share Capital

Special Distributable Capital Reserve

Special Distributable Revenue Reserve

 

Capital Redemption Reserve

 

 

Capital Reserve

 

 

Revenue Reserve

 

 

 

Total

 

£'000

£'000

£'000

£'000

£'000

£'000

£'000

For the year ended 31 December 2010 (unaudited)

Net assets at 1 January 2010

1,394

15,679

37,357

664

98,814

671

154,579

Profit for the year/total comprehensive income

-

-

-

-

15,681

699

16,380

Dividends paid

-

-

(671)

-

-

(578)

(1,249)

Net assets at 31 December 2010

1,394

15,679

36,686

664

114,495

792

169,710

 

 

 

 

 

 

 

 

For the year ended 31 December 2009 (audited)

Net assets at 1 January 2009

1,394

15,679

37,692

664

109,555

587

165,571

Loss for the year/total comprehensive income

-

-

-

-

(10,741)

420

(10,321)

Dividends paid

-

-

(335)

-

-

(336)

(671)

Net assets at 31 December 2009

1,394

15,679

37,357

664

98,814

671

154,579

 

 

 

 

 

 

 

 

 

 

Company

 

 

 

Share Capital

Special Distributable Capital Reserve

Special Distributable Revenue Reserve

 

Capital Redemption Reserve

 

 

Capital Reserve

 

 

Revenue Reserve

 

 

 

Total

 

£'000

£'000

£'000

£'000

£'000

£'000

£'000

For the year ended 31 December 2010 (unaudited)

Net assets at 1 January 2010

1,394

15,679

37,357

664

98,813

672

154,579

Profit for the year/total comprehensive income

-

-

-

-

15,684

696

16,380

Dividends paid

-

-

(671)

-

-

(578)

(1,249)

Net assets at 31 December 2010

1,394

15,679

36,686

664

114,497

790

169,710

 

 

 

 

 

 

 

 

For the year ended 31 December 2009 (audited)

Net assets at 1 January 2009

1,394

15,679

37,692

664

109,555

587

165,571

Loss for the year/total comprehensive income

-

-

-

-

(10,742)

421

(10,321)

Dividends paid

-

-

(335)

-

-

(336)

(671)

Net assets at 31 December 2009

1,394

15,679

37,357

664

98,813

672

154,579

 

 

 

 

 

 

 

 

F&C Private Equity Trust plc

 

Cash Flow Statement

 

 

Year ended

31 December 2010

(Unaudited)

Year ended

31 December 2009

(Audited)

Group

Company

Group

Company

£000

£000

£000

£000

Operating activities

Profit/(loss) before taxation

16,351

16,351

(10,321)

(10,321)

Gains on disposals of investments

(7,373)

(7,373)

(10,914)

(10,914)

(Decrease)/increase in holding losses

(11,565)

(11,568)

23,810

23,811

Exchange differences

(1,000)

(1,000)

(3,767)

(3,767)

Finance costs

3,423

3,423

904

904

Corporation tax refunded/(paid)

137

137

(72)

(72)

Decrease in other receivables

1

40

493

455

Increase/(decrease) in other payables

488

488

(366)

(366)

Net cash inflow/(outflow) from operating activities

 

462

 

498

 

(233)

 

(270)

Investing activities

Purchases of investments

(43,593)

(43,593)

(20,652)

(20,653)

Sales of investments

22,628

22,628

32,083

32,083

Net cash (outflow)/inflow from investing activities

 

(20,965)

 

(20,965)

 

11,431

 

11,430

Financing activities

Repayment of bank loans

-

-

(32,898)

(32,898)

Draw down of bank loans

11,000

11,000

1,800

1,800

Interest paid

(559)

(559)

(769)

(769)

Proceeds from ZDP Share issue

-

-

30,000

-

Loan proceeds from subsidiary

-

-

-

30,000

Issue costs paid

(517)

(517)

(614)

(614)

Equity dividends paid

(1,249)

(1,249)

(671)

(671)

Net cash inflow/(outflow) from financing activities

 

8,675

 

8,675

 

(3,152)

 

(3,152)

Net (decrease)/increase in cash and cash equivalents

 

(11,828)

 

(11,792)

 

8,046

 

8,008

Currency gains

1,000

1,000

1,027

1,027

Net (decrease)/increase in cash and cash equivalents

 

(10,828)

 

(10,792)

 

9,073

 

9,035

Opening cash and cash equivalents

13,509

13,471

4,436

4,436

Closing cash and cash equivalents

2,681

2,679

13,509

13,471

 

 

 

 

Notes (unaudited)

 

1. The unaudited financial results, which were approved by the Board on 30 March 2011, have been prepared in accordance with International Financial Reporting Standards ('IFRS') as adopted by the European Union. Where presentation guidance set out in the Statement of Recommended Practice "Financial Statements of Investment Trust Companies and Venture Capital Trusts" ('SORP') issued by the Association of Investment Companies in January 2009 is consistent with the requirements of IFRS, the Directors have sought to prepare the financial statements on a basis compliant with the recommendations of the SORP.

 

The accounting policies adopted are consistent with those of the previous financial year, except that the following new standards have been adopted in the current year:

 

IFRS 3, Business Combinations (Revised)

IFRS 3 (Revised) introduces significant changes in the accounting for business combinations occurring after becoming effective. Changes affect the valuation of non-controlling interests, the accounting for transaction costs, the initial recognition and subsequent measurement of a contingent consideration and business combinations achieved in stages. The changes will impact the amount of goodwill recognised, the reported results period that an acquisition occurs and future reported results.

 

IAS 27, Consolidated and Separate Financial Statements (Amended)

IAS 27 (Amended) requires that a change in the ownership interest of a subsidiary (without loss of control) is accounted for as a transaction with owners in their capacity as owners. Therefore, such a transaction will no longer give rise to goodwill, nor will it give rise to a gain or loss. Furthermore, the amended standard changes the accounting for losses incurred by the subsidiary as well as the loss of control of a subsidiary.

 

The changes by IFRS 3 (Revised) and IAS 27 (Amended) affect acquisitions or loss of control of subsidiaries and transactions with non-controlling interests after 1 January 2010.

 

The change in accounting policy was applied prospectively and had no material impact on earnings per share.

 

2. Returns per Ordinary Share are based on the following number of shares in issue during the period:

Basic & Diluted: 72,282,273 (2009: 72,282,273)

 

Returns per Restricted Voting Share are based on the average number of shares in issue during the period of 67,084,807 (2009: 67,084,807).

 

Basic & Diluted net asset value per Ordinary Share is based on 72,282,273 (2009: 72,282,273) shares in issue at the end of the period.

 

Net asset value per Restricted Voting Share is based on 67,084,807 (2009: 67,084,807) shares in issue at the end of the period.

 

3. The Board has proposed a final dividend of 0.95p per Ordinary Share, payable on 10 June 2011 to those shareholders on the register on 20 May 2011.

 

4. This results announcement is based on the Group's unaudited financial statements for the year ended 31 December 2010 which have been prepared in accordance with International Financial Reporting Standards as adopted by the EU ('IFRS').

 

5. This announcement is not the Group's statutory accounts. The full audited accounts for the year ended 31 December 2009, which were unqualified, have been lodged with the Registrar of Companies. The statutory accounts for the year to 31 December 2010 (on which the audit report has not been signed) will be delivered to the Registrar of Companies following the Company's Annual General Meeting which will be held at the offices of F&C Asset Management plc, Exchange House, Primrose Street, London, EC2A 2NY on 26 May 2011 at 12 noon.

 

6. The report and accounts for the year will be sent to shareholders and will be available for inspection at the Company's registered office, 80 George Street, Edinburgh EH2 3BU and the Company's website www.fcpet.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR SEDFIUFFSEID
Date   Source Headline
30th Jun 20223:22 pmRNSChange of Name
17th Jun 20224:07 pmRNSTransaction in Own Shares
15th Jun 20225:01 pmRNSTransaction in Own Shares
27th May 20229:08 amRNSResult of Annual Gen Meeting & Directorate Change
26th May 202212:02 pmRNS1st Quarter Results
27th Apr 202210:07 amRNSDirector/PDMR Shareholding
27th Apr 202210:06 amRNSDirector/PDMR Shareholding
27th Apr 202210:04 amRNSDirector/PDMR Shareholding
26th Apr 20223:24 pmRNSDirector/PDMR Shareholding
26th Apr 20223:23 pmRNSDirector/PDMR Shareholding
25th Apr 20229:24 amRNSDirector/PDMR Shareholding
8th Apr 20227:00 amRNSAnnual Financial Report
1st Apr 202210:17 amRNSHolding(s) in Company
1st Apr 202210:09 amRNSHolding(s) in Company
30th Mar 20222:56 pmRNSDirector/PDMR Shareholding
30th Mar 20222:54 pmRNSDirector/PDMR Shareholding
25th Mar 20227:00 amRNSAnnual Financial Report
17th Feb 20227:00 amRNSDirectorate Change
14th Jan 20227:00 amRNSUpdate on Secondary Placing
13th Jan 20227:00 amRNSProposed Secondary Placing
4th Jan 20227:00 amRNSInvestor Presentation
26th Nov 20217:00 amRNS3rd Quarter Results
22nd Nov 202110:47 amRNSHolding(s) in Company
15th Oct 20219:55 amRNSHolding(s) in Company
15th Oct 20217:00 amRNSKepler Trust Intelligence: New Research
27th Aug 20217:00 amRNSInterim results and Quarterly Dividend
25th Jun 20213:14 pmRNSHolding(s) in Company
27th May 20212:15 pmRNSAGM Statement
27th May 202111:51 amRNSQuarterly NAV and Dividend Announcement
29th Apr 20211:01 pmRNSHolding(s) in Company
19th Apr 20217:00 amRNSAnnual Financial Report
26th Mar 20217:00 amRNSFinal Results
24th Mar 20217:00 amRNSInvestment Update
8th Feb 20213:00 pmRNSHolding(s) in Company
9th Dec 20209:22 amRNSHolding(s) in Company
27th Nov 202010:52 amRNSHolding(s) in Company
25th Nov 20209:18 amRNSKepler Trust Intelligence: New Research
20th Nov 20207:00 amRNSQuarterly results and dividend announcement
15th Oct 20204:09 pmRNSNon-Executive Director Declaration
18th Sep 20202:09 pmRNSDirector/PDMR Shareholding
16th Sep 20202:24 pmRNSDirector/PDMR Shareholding
15th Sep 20203:42 pmRNSHolding(s) in Company
1st Sep 202012:24 pmRNSDirector/PDMR Shareholding
21st Aug 20207:00 amRNSInterim Results
20th Jul 20207:00 amRNSNon-Executive Director Declaration
17th Jul 20207:00 amRNSAppointment of Corporate Broker
9th Jun 20209:57 amRNSHolding(s) in Company
4th Jun 20207:00 amRNSDirectorate Change
22nd May 20204:11 pmRNSHolding(s) in Company
21st May 20207:00 amRNSFirst Quarter Results and Dividend Announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.